Cancer research firm makes good progress
Cancer research company N4 Pharma is upbeat about the progress of several of its studies as it continues to build on good results.
The Derbyshire-based company is developing a novel delivery system for cancer treatments and vaccines, Nuvec. It has the potential to help commercialise cancer immunotherapy drugs and improve the effectiveness of viral vaccines.
N4 Pharma’s chief executive Nigel Theobald said: “It has been a busy and productive period for the company across our different work streams. All studies have progressed well to the point where we now have visible timelines for their conclusion throughout the fourth quarter of this year.”
N4 has been working on two collaborations which “have progressed well”. The first agreement is with a major international company working in the gene therapy space and the second is with a UK based pharmaceutical company developing its its own proprietary vaccine for Covid-19 using a DNA plasmid.
Separately it plans to start a three-month proof of concept study within weeks to build on “good results” of a pilot dosage study it undertook earlier this year.
Other studies include a second pilot and a 10-week study looking at tumour models which is about to begin and a fully-funded three-year programme with the University of Queensland looking into the oral application of Nuvec.
